We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pc4.0
Policosanol Research
Likely helps
104 peer-reviewed studies
What the evidence says
Likely helps
Policosanol appears to help in 16 of 16 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1994–2025 with a typical study size of 120 participants.
Based on 104 studies · 13 meta-analyses · 89 RCTs · 16,732 total participants
Confidence
High confidence
What the studies found
16helped· 88 more without graded effect data
By outcome
Cholesterol & lipidsLipid benefits seen in Cuban trials but not replicated by independent RCTs · 6-8 weeks
Likely helps76 studies
Heart & blood pressureLipid benefits seen in Cuban trials but not replicated by independent RCTs · 6-8 weeks
Likely helps33 studies
Glucose & metabolic
Likely helps7 studies
Therapeutic & clinical
Mostly mechanism / observational5 studies
Safety profile
Mostly mechanism / observational5 studies
Liver health
Mostly mechanism / observational3 studies
Cognitive function
Mostly mechanism / observational3 studies
Weight management
Too few graded studies2 studies
By the numbers
Pulled from 29 studies with measurable effects
Likely real effects
92%
across studies
People studied
17k
typical study: 120 people
Strongest designs
102
13 pooled, 89 randomised
Showed benefit
100%
16/16 studies
How long studies ran
1–3 months
11
3+ months
4
Populations Studied
Adults2
Patients with hyperlipidemia2
Hypercholesterolemic patients2
Adults with blood glucose concerns1
Steady research
14 studies in the last 5 years · Latest meta-analysis: 2025
199420092025
1Blood glucose levelsMeta-AnalysisCited 10×n=2,680 · very large study2024
To assess the effects of policosanol on glucose, we employed a random-effects or fixed-effects meta-analysis approach to examine the weighted mean differences (WMDs) and associated 95 % confidence ...
Reza Amini M et al. · Diabetes research and clinical practice (2024)
Noticeable benefit
← WorseNo effectBetter →
Likely real
To assess the effects of policosanol on glucose, we employed a random-effects or fixed-effects meta-analysis approach to examine the weighted mean differences (WMDs) and associated 95 % confidence intervals (CI) before and after policosanol and placebo administration.
Compared to the control group, policosanol supplementation significantly reduced blood glucose levels (WMD: -2.24 mg/dl; 95 % CI: -4.05, -0.42, P = 0.01).
Findings from subgroup analysis revealed a significant reduction of policosanol supplementation on glucose levels in period of less than 24 weeks, and in individuals below 50 years of age.
2Liver enzymes (ALT and AST)Meta-AnalysisCited 3×n=2,535 · very large study2024
Policosanol supplementation exerts a beneficial effect on liver enzymes as well as ALT and AST concentrations in adults.
Gholamrezayi A et al. · Complementary therapies in medicine (2024)
Noticeable benefit
← WorseNo effectBetter →
Likely real
The combination of effect sizes, regarding the random-effects model, demonstrated significant changes in ALT serum levels after intervention (WMD: -1.48 U/L; 95% CI: -2.33 to -0.64; P = 0.001), and AST (WMD: -1.10 U/L; 95% CI: -1.70 to -0.51; P < 0.001).
Policosanol supplementation exerts a beneficial effect on liver enzymes as well as ALT and AST concentrations in adults.
However, further long-term and well-designed RCTs with better quality are needed to further assess and confirm these results.
3LDL-C levelsSystematic ReviewCited 13×n=837 · large study2021
This systemic review shows that the apparent lack of effectiveness of diet manipulation in modulating plasma levels of LDL-C among individuals with HeFH is likely due to biases in study designs, rather than a true lack of effects.
Roy G et al. · Nutrients (2021)
A significant reduction in LDL-C levels was reported in 10 RCTs, including eight dietary supplement interventions (phytosterols, n = 6, omega-3, n = 1; guar gum, n = 1), one food-based intervention and one dietary counseling intervention.
Studies at low risk of biases were more likely to report significant reductions in LDL-C concentrations, compared with studies at risk of bias (chi-square statistic: 5.49; p = 0.02).
This systemic review shows that the apparent lack of effectiveness of diet manipulation in modulating plasma levels of LDL-C among individuals with HeFH is likely due to biases in study designs, rather than a true lack of effects.
4Lipid levelsMeta-AnalysisCited 45×n=1,886 · large study2018
The pooled results supported the lipid-lowering effects and safety of policosanol.
Gong J et al. · Molecular nutrition & food research (2018)
The pooled results supported the lipid-lowering effects and safety of policosanol.
Because of the high heterogeneity, the better treatment effects observed in the Cuban studies and the inconsistent dose-response relationship, more clinical trials are needed to further confirm the efficacy of policosanol on dyslipidemia.
5Plasma lipid and glucose levelsMeta-AnalysisCited 80×n=1,670 · large study2016
Inverse variance-weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid and glucose levels using a random-effects model.
Pirro M et al. · Pharmacological research (2016)
Noticeable benefit
← WorseNo effectBetter →
Likely real
Inverse variance-weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid and glucose levels using a random-effects model.
Overall, WMDs were significant for the impact of NComb supplementation on plasma levels of total cholesterol (-26.15mg/dL, p<0.001), LDL-cholesterol (-23.85mg/dL, p<0.001), HDL-cholesterol (2.53mg/dL, p<0.001), triglycerides (-13.83mg/dL, p<0.001) and glucose (-2.59mg/dL, p=0.010).
NComb-induced amelioration of lipid profile was not affected by duration of supplementation nor by baseline lipid levels; conversely, a greater glucose-lowering effect of NComb was found with higher baseline glucose levels and longer durations of supplementation.
12LDL cholesterol reductionMeta-AnalysisCited 72×n=4,596 · very large study2005
Plant sterols and stanols and policosanol are well tolerated and safe; however, policosanol is more effective than plant sterols and stanols for LDL level reduction and more favorably alters the lipid profile, approaching antilipemic drug efficacy.
Chen JT et al. · Pharmacotherapy (2005)
Large benefit
← WorseNo effectBetter →
Likely real
The net LDL reduction in the treatment groups minus that in the placebo groups was greater with policosanol than plant sterols and stanols (-24% versus -10%, p<0.0001).
Policosanol caused a clinically significant decrease in the LDL:HDL ratio.
Plant sterols and stanols and policosanol are well tolerated and safe; however, policosanol is more effective than plant sterols and stanols for LDL level reduction and more favorably alters the lipid profile, approaching antilipemic drug efficacy.
This meta-analysis confirms that the nutraceutical combination containing berberine, policosanol, and red yeast rice has shown to be an effective product for the improvement of the lipid profile.
Millán J et al. · Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis (2016)
Barely noticeable benefit
← WorseNo effectBetter →
The effect size (relative change from baseline (%)) was -1.3 (9.9%) for total cholesterol, -1.17 (-13.7%) for LDL-c, +0.17 (+3.7%) for HDL-c and -0.24 (-7.0%) for Triglycerides.
This meta-analysis confirms that the nutraceutical combination containing berberine, policosanol, and red yeast rice has shown to be an effective product for the improvement of the lipid profile.
16Systolic and diastolic blood pressureRCTCited 1×n=200 · medium study2025
It is concluded that policosanol 20 mg/day given for 12 weeks to Cuban patients with prehypertension lowered SBP and DBP and produced beneficial changes in the lipid profile, being well tolerated.
Revueltas M et al. · Journal of clinical hypertension (Greenwich, Conn.) (2025)
Huge benefit
← WorseNo effectBetter →
Likely real
Also, more (p < 0.0001) policosanol patients (44%) reached SBP reductions ≥10 mmHg and DBP reductions ≥5 mmHg versus baseline (44% and 61%, respectively) than placebo patients (7% and 22%, respectively).
Nine patients (4.5%) discontinued the trial, none because of AE.
Four patients (3 placebo, 1 policosanol) reported AE.
17Systolic blood pressureRCTn=200 · medium study2025
It is concluded that oral administration of policosanol 20 mg/day for twelve weeks significantly lowered SBP and DBP in Cuban patients with grade I hypertension, and improved lipid profile variables, being safe and well tolerated.
Revueltas Aguero M et al. · Journal of clinical hypertension (Greenwich, Conn.) (2025)
Huge benefit
← WorseNo effectBetter →
Likely real
At study completion, policosanol significantly lowered (p < 0.001) SBP, the primary outcome, by more than 10 mmHg related to baseline and placebo, while also significantly decreasing (p < 0.001) DBP values versus baseline and placebo.
Also, more (p < 0.001) policosanol patients reached SBP reductions ≥10 mmHg and DBP reductions ≥5 mmHg versus baseline (74% and 91%, respectively) than placebo patients (12% and 15%, respectively).
Policosanol significantly lowered low-density lipoprotein-cholesterol (LDL-C) and total cholesterol, while increasing high-density lipoprotein-cholesterol (HDL-C).
18Left ventricular mass reductionRCTCited 18×n=158 · medium study2020
24-week of treatment with AP is associated with a significant reduction in LVM in subjects with MS and LVH, in addition to favourable effects on lipid profile, and could represent an effective strategy aiming at reducing the associated cardiovascular risk.
Mercurio V et al. · Clinical nutrition (Edinburgh, Scotland) (2020)
Barely noticeable benefit
← WorseNo effectBetter →
Likely real
A significant percentage reduction in LVM was observed in AP group vs baseline (-2.7%, p < 0.0001), and compared to placebo (-4.1%, p < 0.0001), and remained significant after adjustment for age, sex, baseline systolic BP and BMI and their changes during the study period.
The proportion of subjects showing LVM reduction was higher in AP group than in the placebo group (57% vs 28%, adjusted p = 0.007).
24-week of treatment with AP is associated with a significant reduction in LVM in subjects with MS and LVH, in addition to favourable effects on lipid profile, and could represent an effective strategy aiming at reducing the associated cardiovascular risk.
The results of this study, applicable to a specific local population show that, in a population of subjects affected by MetS, treatment with AP improves the lipid profile and the most atherogenic factors, thus suggesting a reduction in the risk of development and progression of atherosclerosis, particularly in subjects with high atherogenic risk, due to the presence of sdLDL-C.
Galletti F et al. · Lipids in health and disease (2019)